Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral Levodopa/carbidopa treatment.


Clinical Trial Description

In this study the investigators propose that the retina itself in albinism is deficient in dopamine, and vision improvement will occur as a result of improved retinal function in response to the deficient neurotransmitter dopamine. This study has a pretest-posttest design in order to determine if improvement in vision is in response to replacement of deficiency (dopamine). The electroretinography (ERG) testing and optical coherence tomography (OCT) will be critical determinants to confirm vision improvement as a result of improved retinal function, but are not primary outcome data. Main outcome measures will be collected at pre-treatment, 1 month, 3 months, and 4 months. Change in visual acuity as measured in logMAR by Snellen or sweep visual evoked potential (SVEP) after 3 months of treatment is the primary outcome. Patients include OCA1a patients, OCA1b, OCA2, and unclassified Oculocutaneous albinism (OCA). OCA1a patients clinically are known to have the worst vision, and physiologically have the lowest (or absent) levels of tyrosinase function (Dopamine Production). All patients will be treated with Levodopa/carbidopa 4mg/kg/day in three divided doses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01663935
Study type Interventional
Source University of Wisconsin, Madison
Contact
Status Terminated
Phase Phase 2
Start date October 17, 2012
Completion date April 12, 2018

See also
  Status Clinical Trial Phase
Completed NCT01176435 - Trial of L-DOPA as a Treatment to Improve Vision in Albinism Phase 2
Completed NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Phase 2
Recruiting NCT04281732 - Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed NCT00001153 - Visual Function and Ocular Pigmentation in Albinism N/A
Recruiting NCT05696912 - Functional Tests to Resolve Unsolved Rare Diseases. Rares. N/A
Recruiting NCT06330350 - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases
Completed NCT04658381 - Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population N/A
Completed NCT01838655 - Nitisinone for Type 1B Oculocutaneous Albinism Phase 1/Phase 2